Ray Therapeutics, Inc.
Clinical trials sponsored by Ray Therapeutics, Inc., explained in plain language.
-
New eye injection aims to slow vision loss in rare disease
Disease control Recruiting nowThis early-stage study tests the safety of a single injection of RTx-021 into the eye for people with Stargardt disease, a genetic condition that causes vision loss. Up to 18 participants will receive one of three doses and be followed for 5 years. The goal is to see if the treat…
Phase: PHASE1, PHASE2 • Sponsor: Ray Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New study aims to sharpen vision tests for the blind
Knowledge-focused Recruiting nowThis study is for people with severe vision loss from diseases like retinitis pigmentosa or Stargardt disease. The goal is to find out which vision tests work best for people with very low vision, so future treatments can be measured more accurately. About 25 participants will tr…
Sponsor: Ray Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 22, 2026 14:02 UTC